三阴性和HER-2阳性乳腺癌中肿瘤浸润淋巴细胞研究进展

Recent research progress on tumor infiltrating lymphocytes in triple-negative and HER-2 positive breast cancers

肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)是存在于肿瘤癌巢内及间质中的淋巴细胞群体,其介导的适应性免疫是有效且持续抗肿瘤反应的关键性基础。三阴性乳腺癌(triple-negative breast cancer, TNBC)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性的乳腺癌是最具免疫原性的乳腺癌,TILs在此类乳腺癌中浸润程度较高。近年来研究发现TIL在TNBC和HER-2阳性乳腺癌的预后及新辅助化疗疗效方面有较高的预测效能。本文综述TILs在TNBC及HER-2阳性乳腺癌中的研究进展,为探索乳腺癌新的有效治疗靶点提供理论基础。

Tumor infiltrating lymphocytes （TILs） is a group of lymphocytes that exist in the nests and stroma of tumor. Adaptive immunity mediated by TILs is the key basis for an effective and sustained anti-tumor response. Triple-negative breast cancer （TNBC） and human epidermal growth factor receptor 2 （HER-2） positive breast cancer are the most immunogenic breast cancer in which TILs have a high degree of infiltration. Recent studies have shown that TILs have predictive values in the effectiveness of neoadjuvant chemotherapy and the prognosis of TNBC and HER-2 positive breast cancer. This article reviewed recent research progress on the roles of TIL in TNBC and HER-2 positive breast cancer and the potential of TIL as a new effective therapeutic target for breast cancer.